Since its discovery in 2005, NPM1 mutation in normal karyotype AML has been shown to infer a positive prognostic effect and a major survival advantage in the absence of FLT3‐ITD.8, 19. This evidence concerns the gene FLT3 and acute myeloid leukemia.